Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | OXTR | P30559 | 2/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410361 | 0.91 | OXTR (0.44) | LMNAOXTRAVPR1AKDM4ESMN1; SMN2 | |
| SCHEMBL2406630 | 0.89 | NPC1 (0.43) | LMNAKDM4ESMN1; SMN2TP53KMT2A | |
| SCHEMBL2403390 | 0.87 | DGAT2 (0.42) | LMNAKDM4ESMN1; SMN2KMT2ALPAR1 | |
| SCHEMBL1969820 | 0.84 | OXTR (0.41) | LMNAOXTRAVPR1ATP53KMT2A | |
| SCHEMBL2409952 | 0.83 | TP53 (0.42) | LMNAOXTRAVPR1ATP53KMT2A | |
| SCHEMBL2403444 | 0.83 | KMT2A (0.48) | LMNAKDM4ESMN1; SMN2KMT2ALPAR1 | |
| SCHEMBL1970052 | 0.79 | HCRTR1 (0.48) | LMNAOXTRAVPR1AKDM4ESMN1; SMN2 | |
| SCHEMBL2405626 | 0.76 | ALDH1A1 (0.45) | LMNAOXTRAVPR1AKDM4EKMT2A | |
| SCHEMBL1968992 | 0.75 | ALDH1A1 (0.45) | LMNAOXTRAVPR1AKDM4ESMN1; SMN2 | |
| SCHEMBL2405944 | 0.74 | HCRTR1 (0.43) | OXTRAVPR1ASMN1; SMN2TP53LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | LMNA 2416/4885OXTR 16/4885AVPR1A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.